HNB
ESPR

Huntington National Bank’s Esperion Therapeutics ESPR Stock Holding History

Huntington National Bank’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-160
Closed -$6K – 1616
2020
Q3 		$6K Buy
+160
New +$6.34K ﹤0.01% 1301
2017
Q3 		– Sell
-100
Closed -$5K – 1616
2017
Q2 		$5K Buy
+100
New +$3.68K ﹤0.01% 1380

Other funds holding ESPR

BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
RPAM
Rhenman & Partners Asset Management Stockholm, Sweden $810M AUM 30.2% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Huntington National Bank's ESPR Position: Q4 2020 in Review

Huntington National Bank sold out of Esperion Therapeutics (ESPR) in Q4 2020, closing a stake of 160 shares — an estimated $6K sold.

Huntington National Bank first reported a position in ESPR in Q2 2017 and held it in 2 quarters. The position peaked at $6K in Q3 2020. 157 funds tracked by Wall St. Rank hold ESPR as of Q4 2020.

  • Huntington National Bank reported no remaining Esperion Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Huntington National Bank sold 160 Esperion Therapeutics shares in Q4 2020, an estimated $6K.
  • Huntington National Bank first reported a position in Esperion Therapeutics in Q2 2017 and held it in 2 quarters.
  • Huntington National Bank's Esperion Therapeutics position peaked at $6K in Q3 2020.
  • 157 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q4 2020.

Based on Huntington National Bank's 13F filing for Q4 2020, filed 11 Jan 2021.